- Global Pharma News & Resources

Global Exosome Technologies Market to 2024: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players -

The "Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players" report has been added to's offering.

This explores the application of Exosome technologies within the pharmaceutical and healthcare industries.

Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine, cerebrospinal fluid (CSF) as well as in in vitro cell culture. These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right.

Exosome can be engineered to incorporate targeting ligands, allowing them to deliver cargo selectively to cells. Their small size allows them to penetrate the blood-brain barrier (BBB) for the delivery of central nervous system (CNS) therapies, whereas in cancer they can accumulate within the tumor via enhanced permeability and retention effects. Research within this area remains in the nascent stages, though several clinical studies have been registered within the field.

Although research within the exosome field is in the early stages, the area boasts a broad and diverse pipeline consisting of 22 active products. The majority of these products are within the Preclinical stage of development, and are indicated for the treatment of cancer. Other therapeutic areas strongly represented in this pipeline include the CNS and cardiovascular therapy areas. The clinical trials landscape for exosome therapies is similarly diverse. Since 2006, a total of 124 clinical trials have taken place.

As a result, interest and investment within the field of exosome therapies have been increasing steadily over the past 10 years. Currently there is only one product approved for use on the market, the Exodx Prostate Intelliscore diagnostic test for prostate cancer, developed and marketed by Exosome Diagnostics.

There are a range of companies within the pipeline landscape, most of which have only become established within the past few years. One of the leading companies in this sector is Capricor Therapeutics. The company is forecast to make a profit on the market with a net revenue of $333 million forecast for 2024 attributable to the anticipated successful development of its key product CAP-1002.

This report provides detailed information on the various healthcare applications of exosomes, and assesses the pipeline, clinical trial and company landscapes.


  • What are the features of the exosome lifecycle?
  • How are therapeutic exosomes prepared?
  • How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?
  • Which companies are investing in exosome technologies?
  • How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?

Key Topics Covered:

1 Table of Contents

2 Exosomes in Healthcare
2.1 Overview of Exosomes
2.2 Drug Delivery Systems
2.3 The Exosome Lifecycle
2.4 Exosomes in Biology
2.5 Exosomes in Medicine
2.6 Exosomes as a Therapeutic Target
2.7 Exosomes as Drug Delivery Vehicles
2.8 Therapeutic Preparation of Exosomes
2.9 Exosomes in Therapeutic Research
2.10 Exosomes in Oncology
2.11 Exosomes in CNS Disease
2.12 Exosomes in Other Diseases

3 Assessment of Pipeline Product Innovation
3.1 Overview
3.2 Exosome Pipeline by Stage of Development and Molecule Type
3.3 Pipeline by Molecular Target
3.4 Pipeline by Therapy Area and Indication
3.5 Pipeline Product Profiles
3.5.1 AB-126 - ArunA Biomedical Inc.
3.5.2 ALX-029 and ALX-102 - Alxerion Biotech
3.5.3 Biologics for Autism - Stem Cell Medicine Ltd
3.5.4 Biologic for Breast Cancer - Exovita Biosciences Inc.
3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis - Regenasome Pty
3.5.6 Biologic for Lysosomal Storage Disorder - Exerkine
3.5.7 Biologics for Prostate Cancer - Cells for Cells
3.5.8 CAP-2003 - Capricor Therapeutics Inc.
3.5.9 CAP-1002 - Capricor Therapeutics Inc.
3.5.10 CIL-15001 and CIL-15002 - Ciloa
3.5.11 ExoPr0 - ReNeuron Group Plc
3.5.12 MVAX-001 - MolecuVax Inc.
3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences
3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Codiak BioSciences Inc.
3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology - Evox Therapeutics Ltd
3.5.16 TVC-201 and TVC-300 - Tavec Inc.

4 Assessment of Clinical Trial Landscape
4.1 Interventional Clinical Trials
4.1.1 Clinical Trials by Therapy Type
4.1.2 Clinical Trials by Therapy Area
4.1.3 Clinical Trials by Stage of Development
4.1.4 Clinical Trials by Start Date and Status
4.2 Observational Clinical Trials

5 Company Analysis and Positioning
5.1 Company Profiles
5.1.1 Capricor Therapeutics Inc.
5.1.2 Evox Therapeutics Ltd
5.1.3 ReNeuron Group Plc
5.1.4 Stem Cell Medicine Ltd
5.1.5 Tavec Inc.
5.1.6 Codiak Biosciences Inc.
5.1.7 Therapeutic Solutions International Inc.
5.1.8 ArunA Biomedical Inc.
5.1.9 Ciloa

6 Appendix

For more information about this report visit

View source version on

Editor Details

Last Updated: 22-Nov-2018